Abbott Laboratories (BIT:1ABT)
Italy · Delayed Price · Currency is EUR | Market Cap | 128.30B -37.9% |
| Revenue (ttm) | 39.14B +6.6% |
| Net Income | 5.42B -53.5% |
| EPS | 3.10 -53.6% |
| Shares Out | n/a |
| PE Ratio | 23.66 |
| Forward PE | 15.21 |
| Dividend | 1.56 (2.06%) |
| Ex-Dividend Date | Jan 14, 2026 |
| Volume | n/a |
| Open | 74.00 |
| Previous Close | 74.02 |
| Day's Range | 74.00 - 74.00 |
| 52-Week Range | 70.20 - 118.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott secures CE Mark for Libre Duo, Libre Duo 10 Day
Abbott (ABT) announced it has secured CE Mark for the world’s first dual glucose-ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the…
Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabe...
Abbott: ACS releases updated CRC guidelines reaffirm Cologuard, Cologuard Plus
Abbott (ABT) announced that the American Cancer Society has released updated colorectal cancer screening guidelines that reaffirm Cologuard and Cologuard Plus as preferred noninvasive screening option...
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfol...
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demons...
3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
Walmart ($WMT), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) are the three dividend aristocrat stocks with a Strong Buy rating on Wall Street and payout ratios of more than 50%,…
3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
The article uses TipRanks’ Dividend Aristocrat tool to identify AbbVie ($ABBV), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) as three dividend aristocrat stocks with a Strong Buy rating on Wa...
Jefferies medical supplies analyst holds analyst/industry conference call
Analysts, along with Paul Danello, a US healthcare litigation expert, discuss status and range of outcomes of the federal MDL vs Abbott (ABT) and Reckitt (Mead Johnson) on an Analyst/Industry…
Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery T...
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month ...
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical i...
Abbott Stock Crash: Rebound Could Be Coming Fast
Abbott Laboratories TodayABTAbbott Laboratories$96.42 +0.95 (+1.00%) As of 10:45 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$93.92▼$139.06Dividend Yield2...
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
Abbott Laboratories Earnings Call Transcript: Q1 2026
Q1 results met expectations with 3.7% sales growth and $1.15 adjusted EPS, despite higher financing costs and a weak respiratory season. The Exact Sciences acquisition is integrating well, driving growth in cancer diagnostics, while medical devices and pharma segments delivered strong performances.
Abbott Laboratories Earnings release: Q1 2026
Abbott Laboratories released its Q1 2026 earnings on April 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q1 2026
Abbott Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 16, 2026.
Abbott Laboratories Quarterly report: Q1 2026
Abbott Laboratories has published its Q1 2026 quarterly earnings report on April 16, 2026.
Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.
Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Abbott first-quarter results beat on cancer diagnostics, medical device strength
Abbott marginally beat Wall Street estimates for quarterly profit and revenue on Thursday, partially helped by its newly acquired cancer diagnostics business.
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncolog...
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says
A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for prematur...
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9...
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories NYSE: ABT, a diversified healthcare powerhouse and a member of the elite...
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment...